Apex Laboratories Launches Oral Antiviral “CleVira” Tablets as a Supporting Measure for Mild to Moderate condition of Covid19
Apex Laboratories Launches Oral Antiviral “CleVira” Tablets as a Supporting Measure for Mild to Moderate condition of Covid19
Chennai, India; April 21, 2021:
apex laboratories private limited receives Government of India regulatory approval for Oral Antiviral CleVira Tablets, as a supporting measure for Mild to Moderate condition of COVID-19.
- Manufacturing and Marketing approval granted for Clevira as a supporting measure for Mild to Moderate condition of COVID-19 as an additional indication in addition to its existing Antiviral approval.
- Clevira has shown 86% recovery rate on the 5th day of treatment (86% Patients recovered – RT PCR – CT Value).
- 100% recovery on the 10 day of treatment. Clinical recovery from all signs and symptoms in 4 days.
- One tablet twice daily dosing convenience of oral administration.
- Safe on Liver and Kidney parameters.
Marking a landmark development in the fight against COVID-19 Pandemic in India and around the globe, apex Laboratories Private Limited ,a Chennai based Pharmaceutical manufacturer and exporter known for Research, Innovation and quality medicines for more than four decades, today announced the approval of Antiviral drug Clevira as a supporting measure for Mild to Moderate condition of COVID-19.
About apex laboratories private limited:
apex laboratories private limited is more than 4 decades old Pharmaceutical manufacturer and exporter based at Chennai India, known for its flagship brands such as Zincovit, Prange of Paracetamol and a whole range of branded formulations including dermatology, having global presence in over 30 countries. Research, Innovation and quality are the guiding principles of apex. It is ranked among top 50 Indian pharmaceutical companies. For more information visit www.apexlab.com
References:
1. CTRI/2020/05/025483
2. Ramesh Kannan S et al, International Journal of Innovative Research in Medical Science , Vol 04, Issue 09, Oct 2019